Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials
By
Aesthetic Multispecialty Society
posted
Nov 23, 2020 05:34 AM
0
Recommend
.
0 comments
0 views
Related Content
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials
Aesthetic Multispecialty Society
Added Jun 08, 2020
Blog Entry
Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy
Aesthetic Multispecialty Society
Added Jun 28, 2021
Blog Entry
Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis
Aesthetic Multispecialty Society
Added Jun 08, 2020
Blog Entry
Inadequate response and treatment patterns in adults diagnosed with atopic dermatitis and treated with topical therapy
Aesthetic Multispecialty Society
Added Oct 06, 2021
Blog Entry
Microneedling Plus Topical Pimecrolimus Show Positive Outcomes in Vitiligo Care
Aesthetic Multispecialty Society
Added Jan 05, 2022
Blog Entry
Permalink
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic